Literature DB >> 12355357

Impact of recurrent epidemics of hepatitis a virus infection on population immunity levels: Bristol Bay, Alaska.

Dolly Peach1, Brian J McMahon, Lisa Bulkow, Elizabeth Funk, Rafael Harpaz, Harold S Margolis.   

Abstract

The dynamics of population-based immunity were examined by using serologic surveys of 7 villages in rural Alaska between 2 epidemics of hepatitis A virus (HAV) and after the second epidemic (1988-1990). Among persons aged 2-30 years, the overall age-adjusted prevalence of antibody to HAV (anti-HAV) was 51% in 1983 and 49% in 1993 (P=.506). In children aged <5 years, prevalence rates were 0% and 11% in 1983 and 1993, respectively. The prevalence of HAV infection increased with age in both surveys. When examined by 5-year birth cohorts, anti-HAV prevalence increased in children born between 1979 and 1983 (P<.001). Between the 2 survey periods, 43 clinical cases of HAV infection were reported in these villages; all occurred from 1988 to 1990. Despite high overall prevalence of immunity, transmission during epidemics was facilitated by children aged <15 years susceptible to HAV. Little transmission occurred between epidemics. Vaccination of children against HAV should prevent future epidemics.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12355357     DOI: 10.1086/343815

Source DB:  PubMed          Journal:  J Infect Dis        ISSN: 0022-1899            Impact factor:   5.226


  4 in total

1.  Duration of protection against hepatitis A for the current two-dose vaccine compared to a three-dose vaccine schedule in children.

Authors:  Gregory A Raczniak; Timothy K Thomas; Lisa R Bulkow; Susan E Negus; Carolyn L Zanis; Michael G Bruce; Philip R Spradling; Eyasu H Teshale; Brian J McMahon
Journal:  Vaccine       Date:  2013-03-05       Impact factor: 3.641

2.  Long-term immunogenicity of hepatitis A virus vaccine in Alaska 17 years after initial childhood series.

Authors:  Gregory A Raczniak; Lisa R Bulkow; Michael G Bruce; Carolyn L Zanis; Richard L Baum; Mary M Snowball; Kathy K Byrd; Umid M Sharapov; Thomas W Hennessy; Brian J McMahon
Journal:  J Infect Dis       Date:  2012-11-29       Impact factor: 5.226

3.  Hepatitis B vaccine development and implementation.

Authors:  Hong Zhao; Xiaoying Zhou; Yi-Hua Zhou
Journal:  Hum Vaccin Immunother       Date:  2020-03-18       Impact factor: 3.452

4.  International Circumpolar Surveillance, an Arctic network for the surveillance of infectious diseases.

Authors:  Alan J Parkinson; Michael G Bruce; Tammy Zulz
Journal:  Emerg Infect Dis       Date:  2008-01       Impact factor: 6.883

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.